Liposomal M-V-05: Formulation development and activity testing of a novel dihydrofolate reductase inhibitor for breast cancer therapy
10.3892/ijo-00000669
Saved in:
Main Authors: | Tan, B.J., Quek, K.S., Wong, M.-Y., Chui, W.K., Chiu, G.N.C. |
---|---|
Other Authors: | PHARMACY |
Format: | Article |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/106113 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: Implications on pharmacokinetics and drug toxicities
by: Chiu, G.N.C., et al.
Published: (2014) -
Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model
by: Wong, M.-Y., et al.
Published: (2014) -
DEVELOPMENT OF LIPOSOME FORMULATIONS CO-ENCAPSULATING TOPOISOMERASE INHIBITORS IRINOTECAN AND DOXORUBICIN FOR THE TREATMENT OF OVARIAN CANCER
by: SHAIKH MOHAMMED ISHAQUE
Published: (2012) -
Molecular dynamics of human dihydrofolate reductase
by: Atchara Wijitkosoom
Published: (2010) -
Optimization and therapeutic activity of liposome-conjugated monoclonal antibodies against the ErbB family of receptor tyrosine kinases: First step in the development of therapeutic antibody/liposomal anticancer drug combinations
by: Chiu, G.N.C., et al.
Published: (2014)